Share Twitter LinkedIn Facebook Email Adam Brufsky, MD, PhD of University of Pittsburgh Cancer Institute discusses the MINDACT and HER2 guidelines in genomic profiling for breast cancer.
Atezolizumab Stumbles in Triple Negative Breast Cancer Study: SABCS 2024 Results with Charles Geyer Breast 4 Mins Read